amiodarone has been researched along with Stroke in 58 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anti-arrhythmic agents, like amiodarone, interfere at different stages of the ischemic stroke." | 9.41 | Protective Effects of Intravenous Magnesium Sulfate in Stroke Patients Receiving Amiodarone: A Randomized Controlled Trial. ( Abdollahi, M; Ahmadi, A; Barreto, GE; Ganjali, S; Gheini, M; Mojtahedzadeh, M; Najafi, A; Panahi, Y; Rajaee, SM; Sahebkar, A; Sharifzadeh, M, 2021) |
| "In the ENGAGE AF-TIMI 48 trial, the higher-dose edoxaban (HDE) regimen had a similar incidence of ischaemic stroke compared with warfarin, whereas a higher incidence was observed with the lower-dose regimen (LDE)." | 9.20 | Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. ( Antman, EM; Atar, D; Braunwald, E; Camm, AJ; Giugliano, RP; Heidbuchel, H; Murphy, SA; Ruff, CT; Steffel, J, 2015) |
| "Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin." | 9.19 | Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Al-Khatib, SM; Amerena, J; Avezum, A; Dorian, P; Flaker, G; Garcia, D; Granger, CB; Hanna, M; Harjola, VP; Hohnloser, SH; Hylek, E; Keltai, M; Lopes, RD; Sullivan, RM; Thomas, L; Wallentin, L; Wojdyla, DM, 2014) |
| "Dronedarone is a therapy for the treatment of patients with paroxysmal and persistent atrial fibrillation or atrial flutter." | 9.16 | Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. ( Åkerborg, Ö; Bascle, S; Lindgren, P; Nilsson, J; Reynolds, M, 2012) |
| "Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events." | 9.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "Dronedarone is a multi-channel-blocking drug for the treatment of patients with atrial fibrillation (AF) or atrial flutter (AFL) with rate- and rhythm-controlling properties." | 9.15 | Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2011) |
| "Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin." | 9.01 | Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. ( Avendano, R; Di Biase, L; Diaz, JC; Garcia, MJ; Golive, A; Krumerman, AK; Lupercio, F; Natale, A; Quispe, R; Romero, J, 2019) |
| "Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients." | 9.01 | Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. ( Joung, B; Kim, HJ; Kim, IS; Kim, JY; Kim, TH; Lee, MH; Pak, HN; Uhm, JS; Yu, HT, 2019) |
| "During recent years, systematic reviews of observational studies have compared digoxin to no digoxin in patients with atrial fibrillation or atrial flutter, and the results of these reviews suggested that digoxin seems to increase the risk of all-cause mortality regardless of concomitant heart failure." | 8.98 | Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. ( Feinberg, J; Gluud, C; Jakobsen, JC; Nielsen, EE; Safi, S; Sethi, NJ, 2018) |
| "We performed a systematic review and meta-analysis on the effect of dronedarone on the occurrence of stroke or transient ischemic attack (TIA) in patients with paroxysmal or persistent AF." | 8.87 | Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials. ( Anastasiou-Nana, M; Dagres, N; Iliodromitis, EK; Lekakis, JP; Rallidis, LS; Varounis, C, 2011) |
| "This is a review of 7 studies (DAFNE, ADONIS, EURIDIS, ATHENA, ANDROMEDA, ERATO and DIONYSOS) on dronedarone focusing on efficacy, safety and prevention of stroke." | 8.86 | Impact of dronedarone in atrial fibrillation and flutter on stroke reduction. ( Christiansen, CB; Køber, L; Torp-Pedersen, C, 2010) |
| "Amiodarone has been proposed to decrease atrial fibrillation after cardiac surgery." | 8.83 | Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. ( Bagshaw, SM; Exner, DV; Galbraith, PD; Ghali, WA; Mitchell, LB; Sauve, R, 2006) |
| "Amiodarone is a commonly used pharmacotherapy in patients with atrial fibrillation (AF), with a potential for drug-drug interactions with direct oral anticoagulants (DOACs)." | 8.31 | Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation. ( Andrade, JG; Austin, PC; Caswell, J; Crystal, E; Jackevicius, CA; Ko, DT; Michael, F; Qiu, F; Shurrab, M; Singh, SM; Tu, K, 2023) |
| "In this retrospective cohort study, patients aged 65 years or older with atrial fibrillation treated with amiodarone during apixaban or rivaroxaban use had greater risk for bleeding-related hospitalizations than those treated with flecainide or sotalol." | 8.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "Amiodarone is the most effective antiarrhythmic drug (AAD) for atrial fibrillation (AF), but it has a high incidence of adverse effects." | 7.96 | Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. ( Fonarow, GC; Freeman, JV; Gersh, BJ; Holmes, DN; Kowey, PR; Mahaffey, KW; Naccarelli, GV; Peterson, ED; Piccini, JP; Pokorney, SD; Reiffel, JA; Shrader, P; Singer, DE; Thomas, L; Washam, JB, 2020) |
| " The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter)." | 7.75 | Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| "Patients receiving any of the prophylactic amiodarone regimens used in the Atrial Fibrillation Suppression Trials (AFIST) I and II were matched (1:10 matching) for age, valvular surgery, history of atrial fibrillation, sex, beta-blocker intolerance, and preoperative digoxin therapy with patients not receiving amiodarone prophylaxis." | 7.73 | Impact of prophylactic amiodarone on length of hospital stay, stroke, and atrial fibrillation after cardiothoracic surgery. ( Coleman, CI; Gillespie, EL; Ismaili, A; Kardas, M; Kluger, J; Perkerson, KA; Takata, H; White, CM, 2005) |
| "Amiodarone treated patients had a lower incidence of AF (22." | 6.71 | Amiodarone prevents symptomatic atrial fibrillation and reduces the risk of cerebrovascular accidents and ventricular tachycardia after open heart surgery: results of the Atrial Fibrillation Suppression Trial (AFIST). ( Kluger, J; White, CM, 2003) |
| "The amiodarone pre-treatment group received 50 mg/kg of amiodarone 1 h before MCAO; the amiodarone post-treatment groups received 50 mg/kg of amiodarone immediately after MCAO; the control group received vehicle only." | 5.46 | Neuroprotective effects of amiodarone in a mouse model of ischemic stroke. ( Hishiyama, S; Ishiyama, T; Kotoda, M; Matsukawa, T; Mitsui, K, 2017) |
| "Anti-arrhythmic agents, like amiodarone, interfere at different stages of the ischemic stroke." | 5.41 | Protective Effects of Intravenous Magnesium Sulfate in Stroke Patients Receiving Amiodarone: A Randomized Controlled Trial. ( Abdollahi, M; Ahmadi, A; Barreto, GE; Ganjali, S; Gheini, M; Mojtahedzadeh, M; Najafi, A; Panahi, Y; Rajaee, SM; Sahebkar, A; Sharifzadeh, M, 2021) |
| " Its long-term use may however lead to several adverse effects, including corneal deposits, liver and thyroid gland dysfunction, lung lesions, bone marrow injury, skin lesions, or neurological abnormalities." | 5.35 | Amiodarone induced pneumonitis and hyperthyroidism: case report. ( Ambroziak, U; Bareła, AD; Chazan, R; Grabczak, EM; Opuchlik, A; Potulska, A; Wiwała, J; Zielonka, TM, 2008) |
| "In the ENGAGE AF-TIMI 48 trial, the higher-dose edoxaban (HDE) regimen had a similar incidence of ischaemic stroke compared with warfarin, whereas a higher incidence was observed with the lower-dose regimen (LDE)." | 5.20 | Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. ( Antman, EM; Atar, D; Braunwald, E; Camm, AJ; Giugliano, RP; Heidbuchel, H; Murphy, SA; Ruff, CT; Steffel, J, 2015) |
| "Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin." | 5.19 | Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Al-Khatib, SM; Amerena, J; Avezum, A; Dorian, P; Flaker, G; Garcia, D; Granger, CB; Hanna, M; Harjola, VP; Hohnloser, SH; Hylek, E; Keltai, M; Lopes, RD; Sullivan, RM; Thomas, L; Wallentin, L; Wojdyla, DM, 2014) |
| "Dronedarone is a therapy for the treatment of patients with paroxysmal and persistent atrial fibrillation or atrial flutter." | 5.16 | Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. ( Åkerborg, Ö; Bascle, S; Lindgren, P; Nilsson, J; Reynolds, M, 2012) |
| "Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events." | 5.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "Dronedarone is a multi-channel-blocking drug for the treatment of patients with atrial fibrillation (AF) or atrial flutter (AFL) with rate- and rhythm-controlling properties." | 5.15 | Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2011) |
| "Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin." | 5.01 | Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. ( Avendano, R; Di Biase, L; Diaz, JC; Garcia, MJ; Golive, A; Krumerman, AK; Lupercio, F; Natale, A; Quispe, R; Romero, J, 2019) |
| "Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients." | 5.01 | Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. ( Joung, B; Kim, HJ; Kim, IS; Kim, JY; Kim, TH; Lee, MH; Pak, HN; Uhm, JS; Yu, HT, 2019) |
| "During recent years, systematic reviews of observational studies have compared digoxin to no digoxin in patients with atrial fibrillation or atrial flutter, and the results of these reviews suggested that digoxin seems to increase the risk of all-cause mortality regardless of concomitant heart failure." | 4.98 | Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. ( Feinberg, J; Gluud, C; Jakobsen, JC; Nielsen, EE; Safi, S; Sethi, NJ, 2018) |
| "We performed a systematic review and meta-analysis on the effect of dronedarone on the occurrence of stroke or transient ischemic attack (TIA) in patients with paroxysmal or persistent AF." | 4.87 | Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials. ( Anastasiou-Nana, M; Dagres, N; Iliodromitis, EK; Lekakis, JP; Rallidis, LS; Varounis, C, 2011) |
| " However, dronedarone, a novel antiarrhythmic drug, has been shown to decrease stroke risk by 34% (p = 0." | 4.86 | Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs. ( Crijns, H; Röther, J, 2010) |
| "This is a review of 7 studies (DAFNE, ADONIS, EURIDIS, ATHENA, ANDROMEDA, ERATO and DIONYSOS) on dronedarone focusing on efficacy, safety and prevention of stroke." | 4.86 | Impact of dronedarone in atrial fibrillation and flutter on stroke reduction. ( Christiansen, CB; Køber, L; Torp-Pedersen, C, 2010) |
| "Amiodarone has been proposed to decrease atrial fibrillation after cardiac surgery." | 4.83 | Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. ( Bagshaw, SM; Exner, DV; Galbraith, PD; Ghali, WA; Mitchell, LB; Sauve, R, 2006) |
| "Prophylactic treatment with amiodarone decreases patients' risk of POAF and stroke while reducing LOS." | 4.82 | Effect of prophylactic amiodarone on clinical and economic outcomes after cardiothoracic surgery: a meta-analysis. ( Coleman, CI; Gillespie, EL; Gryskiewicz, KA; Kluger, J; Sander, S; White, CM, 2005) |
| " Trials that assessed whether amiodarone prophylaxis decreases the incidence of postoperative atrial tachyarrhythmias have had mixed results and were not specifically powered to detect changes in cardiovascular morbidity, length of stay, or mortality." | 4.82 | Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. ( Aasbo, JD; Kim, MH; Krishnan, K; Lawrence, AT; Trohman, RG, 2005) |
| "Amiodarone is a commonly used pharmacotherapy in patients with atrial fibrillation (AF), with a potential for drug-drug interactions with direct oral anticoagulants (DOACs)." | 4.31 | Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation. ( Andrade, JG; Austin, PC; Caswell, J; Crystal, E; Jackevicius, CA; Ko, DT; Michael, F; Qiu, F; Shurrab, M; Singh, SM; Tu, K, 2023) |
| "In this retrospective cohort study, patients aged 65 years or older with atrial fibrillation treated with amiodarone during apixaban or rivaroxaban use had greater risk for bleeding-related hospitalizations than those treated with flecainide or sotalol." | 4.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "Amiodarone is the most effective antiarrhythmic drug (AAD) for atrial fibrillation (AF), but it has a high incidence of adverse effects." | 3.96 | Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. ( Fonarow, GC; Freeman, JV; Gersh, BJ; Holmes, DN; Kowey, PR; Mahaffey, KW; Naccarelli, GV; Peterson, ED; Piccini, JP; Pokorney, SD; Reiffel, JA; Shrader, P; Singer, DE; Thomas, L; Washam, JB, 2020) |
| " More specifically, this Mini-Hot-Topic symposium has reviewed for you: (1) the evidence supporting the new novel oral anticoagulants (NOACs) as first-line therapy for prevention of stroke and systemic embolism in patients with "nonvalvular" atrial fibrillation (NVAF); (2) the winding path taken by dronedarone in reaching its current place in our antiarrhythmic armamentarium - in which it still has a role; and (3) the contrasting decisions made with respect to the marketing of vernakalant in Europe versus the United States." | 3.80 | Are we at the goal line with the novel oral anticoagulants and have we reached the end of the line for dronedarone and vernakalant--or is there more to come? ( Reiffel, JA, 2014) |
| " The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter)." | 3.75 | Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| "Patients receiving any of the prophylactic amiodarone regimens used in the Atrial Fibrillation Suppression Trials (AFIST) I and II were matched (1:10 matching) for age, valvular surgery, history of atrial fibrillation, sex, beta-blocker intolerance, and preoperative digoxin therapy with patients not receiving amiodarone prophylaxis." | 3.73 | Impact of prophylactic amiodarone on length of hospital stay, stroke, and atrial fibrillation after cardiothoracic surgery. ( Coleman, CI; Gillespie, EL; Ismaili, A; Kardas, M; Kluger, J; Perkerson, KA; Takata, H; White, CM, 2005) |
| "In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 2521 patients with moderate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs), or placebo." | 2.73 | Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). ( Anderson, J; Bardy, GH; Freudenberger, RS; Halperin, JL; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Poole, J, 2007) |
| "Amiodarone treated patients had a lower incidence of AF (22." | 2.71 | Amiodarone prevents symptomatic atrial fibrillation and reduces the risk of cerebrovascular accidents and ventricular tachycardia after open heart surgery: results of the Atrial Fibrillation Suppression Trial (AFIST). ( Kluger, J; White, CM, 2003) |
| "Minor bleeding was common in both treatment arms, with 738 patients reporting this problem in one or more visits." | 2.71 | Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. ( Corley, SD; DiMarco, JP; Flaker, G; Greene, HL; Mitrani, G; Nemeth, M; Rosenfeld, LE; Safford, RE; Waldo, AL, 2005) |
| "Amiodarone was the most commonly studied agent (10 studies), followed by beta-blockers (8), calcium channel blockers (6) and magnesium (3)." | 2.66 | Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review. ( Bedford, J; O'Bryan, LJ; Petrinic, T; Redfern, OC; Watkinson, PJ; Young, JD, 2020) |
| "Ranolazine is a new antianginal substance which influences the atrial ion channels and leads to a significant reduction of atrial and more specifically ventricular tachyarrhythmias." | 2.46 | [New developments in the antiarrhythmic therapy of atrial fibrillation]. ( Brachmann, J; Ritscher, G; Simon Demel, K; Simon, H; Turschner, O, 2010) |
| "Dronedarone was associated with lower ICH (HR = 0." | 1.91 | Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants. ( Chang, SH; Chen, SW; Huang, CH; Huang, YC; Huang, YT; Hung, KC; Kuo, CF; Tu, HT; Wang, CL; Wu, VC, 2023) |
| "The amiodarone pre-treatment group received 50 mg/kg of amiodarone 1 h before MCAO; the amiodarone post-treatment groups received 50 mg/kg of amiodarone immediately after MCAO; the control group received vehicle only." | 1.46 | Neuroprotective effects of amiodarone in a mouse model of ischemic stroke. ( Hishiyama, S; Ishiyama, T; Kotoda, M; Matsukawa, T; Mitsui, K, 2017) |
| "Eight patients were hospitalized for bradyarrhythmia." | 1.42 | Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis. ( Cho, I; Hartaigh, Bó; Hwang, ES; Joung, B; Lee, HY; Lee, MH; Mun, HS; Pak, HN; Park, JK; Shin, DG; Uhm, JS, 2015) |
| " Its long-term use may however lead to several adverse effects, including corneal deposits, liver and thyroid gland dysfunction, lung lesions, bone marrow injury, skin lesions, or neurological abnormalities." | 1.35 | Amiodarone induced pneumonitis and hyperthyroidism: case report. ( Ambroziak, U; Bareła, AD; Chazan, R; Grabczak, EM; Opuchlik, A; Potulska, A; Wiwała, J; Zielonka, TM, 2008) |
| "Stroke was more frequent in CD (15." | 1.33 | Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas Disease cohort. ( Faiçal, F; Oliveira-Filho, J; Reis, FJ; Torreão, JA; Viana, LC; Vieira-de-Melo, RM; Villar, FA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (32.76) | 29.6817 |
| 2010's | 28 (48.28) | 24.3611 |
| 2020's | 11 (18.97) | 2.80 |
| Authors | Studies |
|---|---|
| Grymonprez, M | 1 |
| Vanspranghe, K | 1 |
| Steurbaut, S | 1 |
| De Backer, TL | 1 |
| Lahousse, L | 1 |
| Shurrab, M | 1 |
| Jackevicius, CA | 1 |
| Austin, PC | 1 |
| Tu, K | 1 |
| Qiu, F | 1 |
| Singh, SM | 1 |
| Crystal, E | 2 |
| Caswell, J | 1 |
| Michael, F | 1 |
| Andrade, JG | 1 |
| Ko, DT | 1 |
| Pallisgaard, J | 1 |
| Greve, AM | 1 |
| Lock-Hansen, M | 1 |
| Thune, JJ | 1 |
| Fosboel, EL | 1 |
| Devereux, RB | 1 |
| Okin, PM | 1 |
| Gislason, GH | 1 |
| Torp-Pedersen, C | 5 |
| Bang, CN | 1 |
| Lin, SY | 1 |
| Liu, YB | 1 |
| Ho, LT | 1 |
| Peng, YF | 1 |
| Kuo, CH | 1 |
| Tang, SC | 1 |
| Huang, CF | 1 |
| Jeng, JS | 1 |
| Wu, VC | 1 |
| Wang, CL | 1 |
| Huang, YC | 1 |
| Tu, HT | 1 |
| Huang, YT | 1 |
| Huang, CH | 1 |
| Chen, SW | 1 |
| Kuo, CF | 1 |
| Hung, KC | 1 |
| Chang, SH | 1 |
| Ray, WA | 1 |
| Chung, CP | 1 |
| Stein, CM | 1 |
| Smalley, W | 1 |
| Zimmerman, E | 1 |
| Dupont, WD | 1 |
| Hung, AM | 1 |
| Daugherty, JR | 1 |
| Dickson, AL | 1 |
| Murray, KT | 1 |
| Pokorney, SD | 1 |
| Holmes, DN | 1 |
| Shrader, P | 1 |
| Thomas, L | 2 |
| Fonarow, GC | 1 |
| Mahaffey, KW | 1 |
| Gersh, BJ | 1 |
| Kowey, PR | 2 |
| Naccarelli, GV | 1 |
| Freeman, JV | 1 |
| Singer, DE | 1 |
| Washam, JB | 1 |
| Peterson, ED | 1 |
| Piccini, JP | 1 |
| Reiffel, JA | 2 |
| Arunachalam, K | 1 |
| Maan, A | 1 |
| Chu, A | 1 |
| Matos, JD | 1 |
| McIlvaine, S | 1 |
| Grau-Sepulveda, M | 1 |
| Jawitz, OK | 1 |
| Brennan, JM | 1 |
| Khabbaz, KR | 1 |
| Sellke, FW | 1 |
| Yeh, R | 1 |
| Zimetbaum, P | 1 |
| O'Bryan, LJ | 1 |
| Redfern, OC | 1 |
| Bedford, J | 1 |
| Petrinic, T | 1 |
| Young, JD | 1 |
| Watkinson, PJ | 1 |
| Panahi, Y | 1 |
| Mojtahedzadeh, M | 1 |
| Najafi, A | 1 |
| Gheini, M | 1 |
| Abdollahi, M | 1 |
| Sharifzadeh, M | 1 |
| Ahmadi, A | 1 |
| Ganjali, S | 1 |
| Rajaee, SM | 1 |
| Barreto, GE | 1 |
| Sahebkar, A | 1 |
| Kotoda, M | 1 |
| Ishiyama, T | 1 |
| Mitsui, K | 1 |
| Hishiyama, S | 1 |
| Matsukawa, T | 1 |
| Sethi, NJ | 1 |
| Nielsen, EE | 1 |
| Safi, S | 1 |
| Feinberg, J | 1 |
| Gluud, C | 1 |
| Jakobsen, JC | 1 |
| Avendano, R | 1 |
| Romero, J | 1 |
| Lupercio, F | 1 |
| Diaz, JC | 1 |
| Quispe, R | 1 |
| Golive, A | 1 |
| Natale, A | 1 |
| Garcia, MJ | 1 |
| Krumerman, AK | 1 |
| Di Biase, L | 1 |
| Kim, IS | 1 |
| Kim, HJ | 1 |
| Yu, HT | 1 |
| Kim, TH | 1 |
| Uhm, JS | 2 |
| Kim, JY | 1 |
| Joung, B | 2 |
| Lee, MH | 2 |
| Pak, HN | 2 |
| Joppi, R | 1 |
| Cinconze, E | 1 |
| Mezzalira, L | 1 |
| Pase, D | 1 |
| Poggiani, C | 1 |
| Rossi, E | 1 |
| Pengo, V | 1 |
| Guo, X | 1 |
| Zhang, Y | 1 |
| Xu, G | 1 |
| Zhou, X | 1 |
| Li, L | 1 |
| Tang, B | 1 |
| Flaker, G | 3 |
| Lopes, RD | 1 |
| Hylek, E | 1 |
| Wojdyla, DM | 1 |
| Al-Khatib, SM | 1 |
| Sullivan, RM | 1 |
| Hohnloser, SH | 5 |
| Garcia, D | 1 |
| Hanna, M | 1 |
| Amerena, J | 2 |
| Harjola, VP | 1 |
| Dorian, P | 2 |
| Avezum, A | 2 |
| Keltai, M | 1 |
| Wallentin, L | 1 |
| Granger, CB | 2 |
| Steffel, J | 1 |
| Giugliano, RP | 1 |
| Braunwald, E | 1 |
| Murphy, SA | 1 |
| Atar, D | 2 |
| Heidbuchel, H | 2 |
| Camm, AJ | 2 |
| Antman, EM | 1 |
| Ruff, CT | 1 |
| Chen, WC | 2 |
| Chen, CY | 1 |
| Wu, BR | 1 |
| Cheng, WC | 1 |
| Lin, KH | 1 |
| Hsia, TC | 1 |
| Chen, W | 1 |
| Chen, CH | 1 |
| Muo, CH | 1 |
| Liao, WC | 1 |
| Li, CH | 1 |
| Qin, D | 1 |
| Leef, G | 1 |
| Alam, MB | 1 |
| Rattan, R | 1 |
| Munir, MB | 1 |
| Patel, D | 1 |
| Khattak, F | 1 |
| Adelstein, E | 1 |
| Jain, SK | 1 |
| Saba, S | 1 |
| Shin, DG | 1 |
| Cho, I | 1 |
| Hartaigh, Bó | 1 |
| Mun, HS | 1 |
| Lee, HY | 1 |
| Hwang, ES | 1 |
| Park, JK | 1 |
| Escobar, C | 1 |
| Arceluz, M | 1 |
| Montes de Oca, R | 1 |
| Mori, R | 1 |
| López-Sendón, JL | 1 |
| Merino, JL | 2 |
| Grabczak, EM | 1 |
| Zielonka, TM | 1 |
| Wiwała, J | 1 |
| Bareła, AD | 1 |
| Opuchlik, A | 1 |
| Potulska, A | 1 |
| Ambroziak, U | 1 |
| Chazan, R | 1 |
| Connolly, SJ | 4 |
| Crijns, HJ | 2 |
| van Eickels, M | 2 |
| Gaudin, C | 2 |
| Page, RL | 2 |
| Schmitt, J | 1 |
| Lewalter, T | 1 |
| Pittrow, D | 1 |
| Duray, G | 1 |
| Goette, A | 1 |
| Brachmann, J | 2 |
| Röther, J | 2 |
| Laufs, U | 1 |
| Christiansen, CB | 1 |
| Køber, L | 1 |
| Crijns, H | 1 |
| Simon, H | 1 |
| Simon Demel, K | 1 |
| Ritscher, G | 1 |
| Turschner, O | 1 |
| Marinelli, A | 1 |
| Capucci, A | 1 |
| Dobrev, D | 1 |
| Ezekowitz, MD | 1 |
| Aikens, TH | 1 |
| Nagarakanti, R | 1 |
| Shapiro, T | 1 |
| Halperin, JL | 2 |
| Joyner, C | 1 |
| Alings, M | 1 |
| Blomström, P | 1 |
| Borggrefe, M | 1 |
| Budaj, A | 1 |
| Chen, SA | 1 |
| Ching, CK | 1 |
| Commerford, P | 1 |
| Dans, A | 1 |
| Davy, JM | 1 |
| Delacrétaz, E | 1 |
| Di Pasquale, G | 1 |
| Diaz, R | 1 |
| Golitsyn, S | 1 |
| Gonzalez-Hermosillo, A | 1 |
| Kautzner, J | 1 |
| Kim, JS | 1 |
| Lanas, F | 1 |
| Lewis, BS | 1 |
| Morillo, C | 1 |
| Murin, J | 1 |
| Narasimhan, C | 1 |
| Paolasso, E | 1 |
| Parkhomenko, A | 1 |
| Peters, NS | 1 |
| Sim, KH | 1 |
| Stiles, MK | 1 |
| Tanomsup, S | 1 |
| Toivonen, L | 1 |
| Tomcsányi, J | 1 |
| Tse, HF | 1 |
| Vardas, P | 1 |
| Vinereanu, D | 1 |
| Xavier, D | 1 |
| Zhu, J | 1 |
| Zhu, JR | 1 |
| Baret-Cormel, L | 1 |
| Weinling, E | 1 |
| Staiger, C | 1 |
| Yusuf, S | 2 |
| Chrolavicius, S | 1 |
| Afzal, R | 1 |
| Shantsila, A | 1 |
| Lip, GY | 2 |
| Dagres, N | 1 |
| Varounis, C | 1 |
| Iliodromitis, EK | 1 |
| Lekakis, JP | 1 |
| Rallidis, LS | 1 |
| Anastasiou-Nana, M | 1 |
| Åkerborg, Ö | 1 |
| Nilsson, J | 1 |
| Bascle, S | 1 |
| Lindgren, P | 1 |
| Reynolds, M | 1 |
| Ahmad, Y | 1 |
| Overbeck, P | 1 |
| Wyse, DG | 3 |
| Waldo, AL | 3 |
| DiMarco, JP | 3 |
| Domanski, MJ | 2 |
| Rosenberg, Y | 2 |
| Schron, EB | 1 |
| Kellen, JC | 2 |
| Greene, HL | 3 |
| Mickel, MC | 1 |
| Dalquist, JE | 1 |
| Corley, SD | 3 |
| Saxonhouse, SJ | 1 |
| Curtis, AB | 1 |
| Yan, GX | 1 |
| Winkel, E | 1 |
| Kao, W | 1 |
| Zimmer, J | 1 |
| Pezzullo, J | 1 |
| Choucair, W | 1 |
| Southard, J | 1 |
| Kokkinos, P | 1 |
| Karasik, P | 1 |
| Greenberg, MD | 1 |
| Singh, SN | 1 |
| Kluger, J | 3 |
| White, CM | 3 |
| Epstein, AE | 1 |
| Geller, N | 1 |
| Josephson, RA | 1 |
| Klein, RC | 1 |
| Krahn, AD | 1 |
| Mickel, M | 1 |
| Mitchell, LB | 2 |
| Nelson, JD | 1 |
| Schron, E | 1 |
| Shemanski, L | 1 |
| Hersi, A | 1 |
| Perkerson, KA | 1 |
| Gillespie, EL | 2 |
| Takata, H | 1 |
| Kardas, M | 1 |
| Ismaili, A | 1 |
| Coleman, CI | 2 |
| Sander, S | 1 |
| Gryskiewicz, KA | 1 |
| Safford, RE | 1 |
| Rosenfeld, LE | 1 |
| Mitrani, G | 1 |
| Nemeth, M | 1 |
| Oliveira-Filho, J | 1 |
| Viana, LC | 1 |
| Vieira-de-Melo, RM | 1 |
| Faiçal, F | 1 |
| Torreão, JA | 1 |
| Villar, FA | 1 |
| Reis, FJ | 1 |
| Aasbo, JD | 1 |
| Lawrence, AT | 1 |
| Krishnan, K | 1 |
| Kim, MH | 1 |
| Trohman, RG | 1 |
| Bagshaw, SM | 1 |
| Galbraith, PD | 1 |
| Sauve, R | 1 |
| Exner, DV | 1 |
| Ghali, WA | 1 |
| O'Donnell, MJ | 1 |
| Valens, N | 1 |
| Lansberg, MG | 1 |
| Wijman, CA | 1 |
| Freudenberger, RS | 1 |
| Hellkamp, AS | 1 |
| Poole, J | 1 |
| Anderson, J | 1 |
| Johnson, G | 1 |
| Mark, DB | 1 |
| Lee, KL | 1 |
| Bardy, GH | 1 |
| Sleik, K | 1 |
| Ginger, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)[NCT00174785] | Phase 3 | 4,628 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors[NCT01151137] | Phase 3 | 3,236 participants (Actual) | Interventional | 2010-07-31 | Terminated (stopped due to The study was stopped because of safety concerns) | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| [NCT00000556] | Phase 3 | 0 participants | Interventional | 1995-03-31 | Completed | ||
| [NCT00224341] | Phase 4 | 360 participants | Interventional | 2003-11-30 | Recruiting | ||
| Risk Factors That Contribute to the Maintenance of Sinus Rhythm: A Prospective Study to Create a Prediction Model for Atrial Fibrillation Patients to Maintain Sinus Rhythm.[NCT04655443] | 77 participants (Actual) | Observational | 2017-08-29 | Terminated (stopped due to due to COVID-19) | |||
| Atrial Fibrillation Lifestyle Project[NCT03724383] | 80 participants (Anticipated) | Interventional | 2018-09-06 | Recruiting | |||
| Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial[NCT02509754] | Phase 4 | 180 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| Catheter Ablation vs. Medical Therapy in Congested Hearts With AF (CATCH-AF in Patients With Impaired LV Function): An Early Ablation Strategy Study Impact on Health Care Utilization[NCT02686749] | Phase 4 | 220 participants (Anticipated) | Interventional | 2016-06-30 | Terminated (stopped due to lack of enrollment) | ||
| A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure[NCT00878384] | 52 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Norwegian Randomized Study of Persistent Atrial Fibrillation Treatment: Cryoballoon Versus Radiofrequency Catheter Ablation (NO PERS-AF)[NCT03008811] | 101 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| Pre-Operative Stellate Ganglion to Prevent Post-Operative Atrial Fibrillation[NCT05656170] | 0 participants (Actual) | Interventional | 2023-10-01 | Withdrawn (stopped due to Unable to begin study) | |||
| A Randomized Controlled Trial of Prophylactic Pulmonary Vein Isolation as Adjunct to Coronary Artery Bypass Grafting[NCT00338715] | Phase 3 | 193 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving an Amniotic Membrane Patch Placed on the Epicardial Surface[NCT02193321] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2014-07-31 | Withdrawn | ||
| Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement - a Randomized Controlled Trial[NCT05076019] | 266 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins - Randomized Controlled Trial[NCT05062239] | 100 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 63 |
| Placebo | 90 |
The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 65 |
| Placebo | 94 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 116 |
| Placebo | 139 |
The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 675 |
| Placebo | 859 |
The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 734 |
| Placebo | 917 |
Deaths were classified according to the primary cause of death. (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any death | - Cardiovascular death | --- Cardiac arrhythmic death | |
| Dronedarone | 25 | 21 | 13 |
| Placebo | 13 | 10 | 4 |
AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study. (NCT01151137)
Timeframe: from first study drug intake up to 10 days after the last study drug intake
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any AE | - Any serious AE | - Any AE leading to death | - Any AE leading to treatment discontinuation | - Any AE leading to hospitalization | |
| Dronedarone | 797 | 113 | 4 | 212 | 95 |
| Placebo | 600 | 77 | 0 | 80 | 71 |
(NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| MI or unstable angina pectoris | - MI | Stroke | - Ischemic stroke | Systemic arterial embolism | Episode of heart failure | - Hospitalization due to heart failure | Unplanned hospitalization for cardiovascular cause | |
| Dronedarone | 15 | 3 | 23 | 18 | 1 | 115 | 43 | 113 |
| Placebo | 8 | 2 | 10 | 9 | 0 | 55 | 24 | 59 |
"First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions [MI], or cardiovascular death.~Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause.~Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks [TIA], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |
|---|---|---|
| First co-primary endpoint | Second co-primary endpoint | |
| Dronedarone | 43 | 127 |
| Placebo | 19 | 67 |
"Time to cardiovascular death was defined as the time from randomization to the death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.003 | 0.005 | 0.008 | 0.022 | 0.026 | 0.026 |
| Placebo | 0.001 | 0.003 | 0.004 | 0.004 | 0.027 | 0.027 |
"Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.009 | 0.013 | 0.021 | 0.042 | 0.045 | 0.045 |
| Placebo | 0.002 | 0.003 | 0.007 | 0.013 | 0.038 | 0.038 |
"Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.020 | 0.034 | 0.069 | 0.110 | 0.137 | 0.137 |
| Placebo | 0.005 | 0.014 | 0.033 | 0.059 | 0.099 | 0.099 |
22 reviews available for amiodarone and Stroke
| Article | Year |
|---|---|
Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.
Topics: Administration, Oral; Amiodarone; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Mem | 2023 |
Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy | 2020 |
Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Atrial Fibrillation; Calcium Channel Blockers; Criti | 2020 |
Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Bias; Calcium Channel Blockers; Comorbidity; | 2018 |
Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; | 2019 |
Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anticoagulants; ATP Binding Cassette Transporter, Sub | 2019 |
[Clinical profile of the new antiarrhythmic drug dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedaro | 2010 |
[Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabi | 2010 |
Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedaro | 2010 |
Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Fi | 2010 |
[New developments in the antiarrhythmic therapy of atrial fibrillation].
Topics: Acetanilides; Aged; Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dron | 2010 |
Antiarrhythmic drugs for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; | 2011 |
Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Incidence; Ischemic At | 2011 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzi | 2012 |
Risks and benefits of rate control versus maintenance of sinus rhythm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; D | 2003 |
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati | 2003 |
Meta-analysis of antiarrhythmic therapy in the prevention of postoperative atrial fibrillation and the effect on hospital length of stay, costs, cerebrovascular accidents, and mortality in patients undergoing cardiac surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiac Surgica | 2003 |
Management of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Atrial Fibrillation; Heart Rate; Humans; Recurr | 2005 |
Effect of prophylactic amiodarone on clinical and economic outcomes after cardiothoracic surgery: a meta-analysis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Coronary | 2005 |
Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgic | 2006 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2002 |
11 trials available for amiodarone and Stroke
| Article | Year |
|---|---|
Protective Effects of Intravenous Magnesium Sulfate in Stroke Patients Receiving Amiodarone: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Amiodarone; Anti-Arrhythmia Agents; Humans; Magnesium Sulfate; Stroke | 2021 |
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Brazil; Cause of Deat | 2014 |
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Hemorrhage; H | 2015 |
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cause of Death; Comb | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Computer Simulation; Cost Sav | 2012 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
A comparison of rate control and rhythm control in patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2002 |
Amiodarone prevents symptomatic atrial fibrillation and reduces the risk of cerebrovascular accidents and ventricular tachycardia after open heart surgery: results of the Atrial Fibrillation Suppression Trial (AFIST).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial | 2003 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2004 |
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Mod | 2005 |
Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Defibrillator | 2007 |
25 other studies available for amiodarone and Stroke
| Article | Year |
|---|---|
Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Adult; Aged, 80 and over; Amiodarone; Anticoagulants; Atrial Fibrillation; Cas | 2023 |
Atrial fibrillation onset before heart failure or vice versa: what is worst? A nationwide register study.
Topics: Amiodarone; Anticoagulants; Antihypertensive Agents; Atrial Fibrillation; Brain Ischemia; Heart Fail | 2023 |
Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anticoagulants; Atrial Fibrillation; Gastrointestinal Hemorrhage; | 2023 |
Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Brain | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; | 2023 |
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Contraindications, | 2020 |
Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Canada; Clinical Deci | 2021 |
Neuroprotective effects of amiodarone in a mouse model of ischemic stroke.
Topics: Amiodarone; Animals; Brain Ischemia; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Neuropr | 2017 |
Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cl | 2013 |
Are we at the goal line with the novel oral anticoagulants and have we reached the end of the line for dronedarone and vernakalant--or is there more to come?
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Embo | 2014 |
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comor | 2014 |
Amiodarone use is associated with increased risk of stroke in patients with nonvalvular atrial fibrillation: a nationwide population-based cohort study.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Comorbid | 2015 |
Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; | 2016 |
Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2015 |
Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relatio | 2017 |
Amiodarone induced pneumonitis and hyperthyroidism: case report.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Humans; Hyperthyro | 2008 |
Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrill | 2009 |
Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2011 |
Atrial fibrillation: outpatient presentation and management.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-A | 2011 |
Dronedarone: a new hope for stroke prevention in atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Risk Factors; Stroke | 2011 |
[Update 2012: new European guidelines for atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Dronedarone; Germany; Humans; Long-Term Care; Pract | 2012 |
Impact of prophylactic amiodarone on length of hospital stay, stroke, and atrial fibrillation after cardiothoracic surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Cohort S | 2005 |
Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas Disease cohort.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Chagas Disease; Cohort Studies; Fem | 2005 |
Summaries for patients. Potential benefits of amiodarone for patients undergoing open-heart surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
Thyroid replacement therapy and atrial fibrillation in acute ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bra | 2006 |